Observational studyDiabetes, obesity & metabolism2025
Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes.
Observational study in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes.Diabetes, obesity & metabolism · 2025Observational
- PATHOGENESIS OF ACUTE DIABETIC CHARCOT ARTHROPATHY IN THE FOOT AND ANKLE: A COMPREHENSIVE LITERATURE REVIEW.Orthopedic reviews · 2025Article
- Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes.BMJ open diabetes research & care · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
aimsDiabetic foot complications are a growing challenge for both individuals and society, underscoring the need for medical treatments and reliable risk markers. This study aimed to identify circulating metabolites associated with the prevalence and incidence of diabetic foot complications in individuals with type 1 diabetes (T1D). MATERIALS AND
methodsA non-targeted panel of 75 serum metabolites was measured via mass spectrometry in 637 individuals with T1D from the Steno Diabetes Center Copenhagen, with a median follow-up of 10 years. Associations with diabetic foot complications (foot ulcers and lower extremity amputations) were assessed using linear regression for prevalent and Cox models for incident outcomes. Metabolites with significant crude associations (after multiple testing correction) were further adjusted for key confounders including demographics, clinical variables, lipid profile and renal function, using R statistics.
resultsParticipants had a median (interquartile range) age of 55 (47, 64) years, diabetes duration of 35 (25, 44) years and HbA1c levels of 64 (8%) (56, 72 (7.3%, 8.7%)) mmol/mol. In crude models, six metabolites were associated with prevalent amputations and 11 with incident ulcers. After adjustment, threonine and succinic acid remained associated with prevalent amputations (p < 0.05). Ribonic acid (Hazard Ratio [HR] per percentage-increase: 1.02; 95% CI: 1.00-1.04) and nonanoic acid (HR: 0.96; 95% CI: 0.94-0.99) remained significantly associated with incident ulcers. The association between ribonic acid and incident diabetic foot ulcers was replicated in an independent cohort (p < 0.05).
conclusionsThis study identified novel circulating metabolites, particularly those of the pentose phosphate pathway, associated with the risk of diabetic foot complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.